Luteolin Was Given Before Methamphetamine in This Mouse Withdrawal Study
An intervention administered before each drug exposure is not the same experiment as treating established withdrawal symptoms afterward. Gao and colleagues examined luteolin in a mouse model of methamphetamine exposure and withdrawal. That timing limits the clinical claims the results can support.
The treatment preceded the exposure
The methods describe intraperitoneal luteolin at 20 mg/kg, given 30 minutes before methamphetamine at 3 mg/kg. The experimental conditions included vehicle and saline comparisons. Behavioral and molecular assessments then examined outcomes associated with withdrawal.
These administered animal doses and routes are protocol details. They do not establish an oral supplement dose or a treatment regimen for people who have already developed persistent symptoms.
Outcomes depended on time and task
The authors reported no anxiety-like behavior at the early 48–72-hour withdrawal assessment, but differences emerged about a week after withdrawal. Novel-object recognition differed at a 24-hour interval but not at the three-hour interval. Other tasks assessed spontaneous alternation, sucrose preference and swimming immobility.
Those contrasts matter. “Cognitive deficit” and “negative emotions” summarize several operational measures; they should not erase the null findings or become human clinical diagnoses.
Molecular findings accompanied selected behavioral effects
Luteolin pretreatment partially attenuated the reported behavioral abnormalities and altered findings involving AKT, FOXO1 and HO-1 in the prefrontal cortex and caudate putamen. These results support investigation of a proposed pathway in the model.
They do not demonstrate that every behavioral effect was exclusively caused by that pathway, nor establish that the same molecular measurements identify a person’s current impairment.
Translation remains a separate question
The paper did not conduct a human withdrawal-treatment trial or test whether starting luteolin after a completed exposure reverses longstanding injury. A favorable experimental pretreatment result cannot answer those questions without additional evidence.
Scientific source
Gao B and colleagues. Luteolin Potentially Alleviates Methamphetamine Withdrawal-Induced Negative Emotions and Cognitive Deficits Through the AKT/FOXO1/HO-1 Signaling Pathway in the Prefrontal Cortex and Caudate Putamen. International Journal of Molecular Sciences (2025),26:5739. DOI:10.3390/ijms26125739. Original commentary on the supplied study.



